
William Koster Email and Phone Number
William Koster's Contact Details
William Koster work email
- Valid
- Valid
- Valid
William Koster personal email
William Koster phone numbers
William Koster Work Experience Details
-
Director (Chairman 2020-2021; Vice-Chairman 2021-Present)Ocuterra Therapeutics (Previously Named Scifluor Life Sciences) Apr 2020 - PresentGreater Boston
-
-
President And CeoNorthern Pilot Company, Llc Dec 2008 - PresentGreater Boston AreaNorthern Pilot Company, LLC is a private consulting company providing strategic guidance to the pharmaceutical industry. The firm specializes in developing and optimizing business and R&D strategies and practices, portfolio management, evaluation of R&D assets, licensing and M&A, activities.
-
Director (Chairman)Scifluor Life Sciences, Llc (Renamed Ocuterra Therapeutics) Mar 2015 - Aug 2020Cambridge, Ma
-
DirectorCadent Therapeutics (Luc And Ataxion Merger) Dec 2017 - Sep 2018Cambridge, Ma
-
Director (Chairman 2013-2016)Vedantra Pharmaceuticals Inc. (Renamed Elicio Therapeutics) Dec 2013 - Sep 2018Cambridge, Ma
-
DirectorLuc Therapeutics Inc. (Previously Named Mnemosyne) Jul 2013 - Mar 2017Cambridge, Ma
-
President And CeoNeurogen Corporation Sep 2001 - Feb 2008Neurogen (Nasdaq symbol: NRGN), a public company in the biotechnology sector (subsequently acquired by Ligand Pharmaceuticals, Inc.) focused on creating small molecule drugs and spanning the R&D continuum from screen development, lead identification, lead optimization, preclinical development, through clinical proof-of-concept and up to Phase 3. R&D programs targeted four therapeutic areas: neuroscience, pain, inflammation, and diabetes/obesity. The clinical development portfolio consisted of two alpha-3 preferring, partial GABA agonists (adipiplon (Phase 2) and NG2-83 (Phase 1) for insomnia, anxiety, and schizophrenia, a partial D2 agonist (aplindore) in-licensed from Wyeth for Parkinson’s Disease (Phase 2) and RLS (Phase 2), a MCH-1 antagonist for obesity/biabetes (Phase 1b) and a VR-1 antagonist (NGD-8243 (MK-2295)) out-licensed to Merck for treatment of pain (Phase 2)
-
Senior Vice-PresidentBristol-Myers Squibb Dec 1971 - Aug 2001Began career at The Squibb Institute in basic research and ultimately, as SVP of the BMS Pharmaceutical Research Institute, lead worldwide drug discovery, preclinical development, and exploratory clinical development operations through Phase 2a. As head of the Institute's R&D assessment and integration team, performed the due diligence and valuation of the R&D assets leading to the acquisition of the DuPont Pharmaceutical Company.
William Koster Education Details
-
Tufts UniversityChemistry
-
Colby CollegeChemistry
Not the William Koster you were looking for?
-
1comcast.net
-
2veeva.com, crossix.com
-
3lonza.com, qaconsultoria.com.br, qaconsultoria.com.br
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trialFrequently Asked Questions about William Koster
What company does William Koster work for?
William Koster works for Exithera Pharmaceuticals Inc.
What is William Koster's role in his/her workplace?
William Koster's role in his/her workplace is Director (Chairman) At Ocuterra Therapeutics (Formerly Scifluor Life Sciences).
What is William Koster's email address?
William Koster's email address is wi****@****uor.com
What is William Koster's direct phone number?
William Koster's direct phone number is +161768*****
What schools did William Koster attend?
William Koster attended Tufts University, and Colby College .
What is William Koster's role in his/her workplace?
William Koster has skills like Pharmaceutical Industry, Drug Discovery, Biotechnology, Clinical Development, R&d, Strategy, Clinical Trials, Clinical Research, Therapeutic Areas, Neuroscience, Lead Change, Program Management, Biopharmaceuticals, Drug Development, Commercialization, Technology Transfer, and Life Sciences.